Alebund Pharmaceuticals (Jiangsu) Limited (HKG:9637)
Hong Kong · Delayed Price · Currency is HKD 28.80
+0.30 (1.05%)
At close: Sep 4, 2026
Alebund Pharmaceuticals (Jiangsu) Company Description
Alebund Pharmaceuticals (Jiangsu) Limited operates as a biopharmaceutical company that develops therapies for kidney diseases and their complications in China and Hong Kong.
Its products include AP301, a phosphate binder; AP306, a sodium-dependent phosphate transport protein inhibitor; one early-clinical-stage product candidate AP303; and four preclinical product candidates, including AP308, AP304, AP305, and AP307.
Alebund Pharmaceuticals (Jiangsu) Limited was founded in 2018 and is headquartered in Yangzhou, China.
Alebund Pharmaceuticals (Jiangsu) Limited
| Country | China |
| Founded | 2018 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 169 |
| CEO | Guoyao Xia |
Contact Details
Address: Building 7 Yangzhou China | |
| Website | alebund.com |
Stock Details
| Ticker Symbol | 9637 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Guoyao Xia Ph.D. | Co-Founder, Chairman and Chief Executive Officer |
| Dr. Jin Tian M.D. | Co-Founder, Chief Medical Officer and Executive Director |
| Dr. Huading Zhang Ph.D. | Chief Operating Officer and Executive Director |
| Yun Wang | Chief of Staff and Executive Director |
| Yongli Liu | Finance Director |
| Dr. Chutian Shu Ph.D. | Chief Technology Officer |
| Dr. Shen Xiao M.D., Ph.D. | Chief Scientific Officer |
| Jun Feng | Head of commercialization |
| Nanyou Chen | Joint Company Secretary |
| Yu Yeung Tse | Joint Company Secretary |